AstraZeneca (AZN) Given a GBX 5,500 Price Target by JPMorgan Chase & Co. Analysts

AstraZeneca (LON:AZN) has been given a GBX 5,500 ($77.12) price target by JPMorgan Chase & Co. in a research note issued on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price objective would indicate a potential upside of 15.30% from the stock’s previous close.

A number of other equities analysts have also recently commented on the stock. Goldman Sachs Group reiterated a “sell” rating and issued a GBX 3,800 ($53.28) target price on shares of AstraZeneca in a research report on Tuesday, October 17th. Barclays reiterated an “overweight” rating and issued a GBX 6,300 ($88.33) target price on shares of AstraZeneca in a research report on Monday, December 18th. Credit Suisse Group upgraded shares of AstraZeneca from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from GBX 4,800 ($67.30) to GBX 5,800 ($81.32) in a research report on Monday, October 16th. Deutsche Bank lifted their target price on shares of AstraZeneca from GBX 5,600 ($78.52) to GBX 5,700 ($79.92) and gave the stock a “buy” rating in a research report on Tuesday, December 5th. Finally, Morgan Stanley set a GBX 4,700 ($65.90) target price on shares of AstraZeneca and gave the stock a “neutral” rating in a research report on Friday, October 20th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. AstraZeneca currently has an average rating of “Hold” and an average price target of GBX 5,211.65 ($73.07).

Shares of AstraZeneca (LON:AZN) traded down GBX 75 ($1.05) during trading hours on Thursday, reaching GBX 4,770 ($66.88). 2,790,000 shares of the company were exchanged, compared to its average volume of 2,020,000. The stock has a market cap of $60,400.00 and a PE ratio of 2,805.88. AstraZeneca has a one year low of GBX 4,260 ($59.73) and a one year high of GBX 5,520 ($77.40).

In other AstraZeneca news, insider Philip A. J. Broadley acquired 415 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were acquired at an average price of GBX 4,846 ($67.95) per share, with a total value of £20,110.90 ($28,198.12).

COPYRIGHT VIOLATION NOTICE: “AstraZeneca (AZN) Given a GBX 5,500 Price Target by JPMorgan Chase & Co. Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/11/astrazeneca-azn-given-a-gbx-5500-price-target-by-jpmorgan-chase-co-analysts-2.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply